Authors
Latest:
Identifying Small Clinical Characteristics to Facilitate Early Myasthenia Gravis Diagnosis: Judith Thompson, PharmD, MPH, CPHQThe rare disease population health strategy lead at UCB provided clinical insight on some of the unique challenges of diagnosing myasthenia gravis, and some of the early signs clinicians and non-specialists should look out for. [WATCH TIME: 3 minutes]
Latest:
Unveiling the Connection Between Migraine and the Gut: Daping Yang, PhDThe postdoctoral researcher at Harvard Medical School discussed the relationship between sensory neurons and the neuropeptide CGRP in regulating gut immunity. [WATCH TIME: 6 minutes]
Latest:
Using SEEG Data to Decode Brain Activity for Decision-Making: Alexander C. Whiting, MDThe director of epilepsy surgery at Allegheny Health Network talked about recent advances in brain signal analysis with stereoelectroencephalography and its potential for transforming care for decision-making disorders. [WATCH TIME: 4 minutes]
Latest:
Innovation in Stroke Care and Expanding the Treatment Windows: Keith Churchwell, MD, FAHA, FACC, FACPThe president of the American Heart Association discussed how precision medicine, advanced imaging, and expanded treatment windows are transforming stroke care, as displayed at ISC 2025. [WATCH TIME: 5 minutes]
Latest:
Ways to Optimize Trials for ALS Drug Development: Richard Bedlack, MD, PhD, MSThe director of the Duke ALS Clinic at Duke Health discussed the advances in drug development for ALS and ways to evolve future trials to get optimal therapeutic benefit. [WATCH TIME: 3 minutes]
Latest:
Categorizing Biomarker Criteria for Alzheimer Disease Diagnosis and Staging: Clifford R. Jack Jr., MDThe neuroradiologist at Mayo Clinic discussed the categorization of biomarkers for Alzheimer disease, focusing on core biomarkers specific to the disease and those reflecting related pathologies. [WATCH TIME: 8 minutes]
Latest:
Continued Evolution of Deep Brain Stimulation in Neurology: Jonathan Jagid, MD; Brian Noga, PhDA pair of neurologists from the University of Miami Miller School of Medicine provided insight on the various ways deep brain stimulation has changed and the potential treatment opportunities that lie ahead. [WATCH TIME: 4 minutes]
Latest:
Effectiveness of Zavegepant in Treating Migraine With and Without Aura: Timothy Smith, MDThe chief executive officer and president of Study Metrics Research provided commentary on a large-scale analysis further demonstrating efficacy and safety of zavegepant, regardless of aura status. [WATCH TIME: 3 minutes]
Latest:
Clinical Validation and Real-World Impact of PrecivityAD2 Test for Alzheimer Diagnosis: Joel B. Braunstein, MDThe CEO at C2N Diagnostics talked about the clinical utility of the company’s PrecivityAD2 test, which uses the p-tau 217 biomarker and amyloid-β measurements, to increase diagnostic confidence and influence treatment decisions in Alzheimer disease. [WATCH TIME: 7 minutes]
Latest:
Utilizing Aspirin to Lower Stroke Rates in Cerebral Amyloid Antipathy: Sheheryar Jamali, MDThe neurologist from Mayo Clinic discussed his abstract at AAN 2021 comparing stroke rates in patients with cerebral amyloid antipathy given treatment with aspirin.
Latest:
Clarifying the Role of Cannabinoids in Agitation Management for Alzheimer Disease: Brent Forester, MD, MScThe chair of psychiatry at Tufts University School of Medicine discussed ongoing research exploring the potential of cannabinoids in treating agitation in Alzheimer disease. [WATCH TIME: 5 minutes]
Latest:
An Overview of Therapeutic Options for Amyotrophic Lateral SclerosisWith an anticipated life expectancy of 3 years from the time of symptom onset, an effective treatment strategy is essential in ALS—and recent therapeutic progress has built a foundation of hope for the community.
Latest:
Best Practices for Collaborative Migraine CareDr Williams discusses best practices for taking care of patients with migraine in a collaborative manner.
Latest:
Addressing Persistent Challenges in NMOSD Diagnosis and Treatment: Sumaira AhmedDespite advancements in NMOSD treatments, the founder and executive director of the Sumaira Foundation discussed how misdiagnosis, delayed diagnosis, and disparities in care remain significant challenges. [WATCH TIME: 4 minutes]
Latest:
Resources for Sleep DisordersDrs C. Michael Gibson, Ashgan A. Elshinawy, and Nathaniel F. Watson share resources for the treatment of sleep disorders.
Latest:
A Changing Clinical Landscape: Promising Therapeutic Avenues in the Treatment of DIPG and Other Diffuse Midline GliomasA duo of experts from Weill Cornell Medicine talked about the advancements made in diffuse midline gliomas research and clinical trials that may offer new hope for improving its historically poor prognosis.
Latest:
Emerging Treatment Landscape and Future Outlook for Friedreich AtaxiaAn expert discusses how vatiquinone targets Friedreich ataxia in patients with balance issues by inhibiting 15-lipoxygenase to reduce oxidative stress. Novel dual-route gene therapy combines systemic IV and targeted dentate nuclei delivery, addressing both central and peripheral manifestations while potentially offering disease-modifying benefits.
Latest:
Artificial Intelligence, Myelin Repair, and Aging as Emerging Frontiers in MS Research: Bruce Bebo, PhDThe executive vice president of research at National MS Society talked about how advancements in the field of neurology are shaping new approaches to diagnosing, monitoring, and treating multiple sclerosis. [WATCH TIME: 5 minutes]
Latest:
Advocating for Patients With Migraine Through Research Initiatives: Serena L. Orr, MD, MScThe pediatric neurologist and headache specialist at the University of Calgary and Alberta Children’s Hospital spoke about the need for improved funding and research efforts for the migraine population. [WATCH TIME: 5 minutes]
Latest:
Lifestyle Change for Migraine Management: Practical Tips for the Neurologist and PCP, Part 2Trigger avoidance-only strategies don’t actually help migraine patients improve. These are the proactive behaviors that do.
Latest:
Current and Future Landscape of Alzheimer Disease Treatment: Emergence of Disease Modifying TherapiesAfter years of failed drug development, the thoughts of disease-modifying therapies for Alzheimer disease are starting to become real.
Latest:
Exploring New Avenues for Treating Muscular Dystrophies With Targeted Therapies: Matthew Alexander, PhDThe associate professor of pediatric neurology and genetics at the University of Alabama Birmingham provided clinical insights on the key signaling pathways currently being targeted in the treatment of muscular dystrophies. [WATCH TIME: 4 minutes]
Latest:
Future Directions and Takeaways Regarding Anti-CD20 Therapies in MSAhmed Obeidat, MD, PhD, Riley Bove, MD, Stephen Krieger, MD, and Erin Longbrake, MD, PhD, share perspectives on the future of MS care, the importance of vigilance in lab testing, and why patients may need reassurance about the potential for disease control with currently available therapies.
Latest:
Managing MS in MillennialsEffectively navigating the nuances of this unique patient population will ultimately help drive innovative solutions for this generation and those to come.
Latest:
Future Directions on Understanding the Link Between Wildfire Particulates and Dementia: Joan A. Casey, PhD & Holly Elser, MD, PhD, MPHA duo of experts highlighted the need for further studies on the exploration of how exposure to wildfire particulate matter impacts neurodegenerative diseases. [WATCH TIME: 2 minutes]
Latest:
Leah Croll, MD: Importance of Mental Health of Clinicians During COVID-19 PandemicThe neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic.
Latest:
Microglia’s Role in MS and Other Neurodegenerative Diseases: Daniel Reich, MD, PhDThe senior investigator at the National Institutes of Neurological Disorders and Stroke spoke about new opportunities for research into brain lesions and microglia.
Latest:
Switching MG Treatment Due to Adverse Events or Poor Disease ControlExpert neurologists share approaches to switching MG treatment due to either poor disease control or adverse events.
